Effective and less toxic reversal of low-molecular weight heparin anti- coagulation by a designer variant of protamine. J Vasc Surg. 1995;21(5):839-850. 180. Wake eld TW, Andrews PC, Wrobleski SK, et al. A [118RGD] protamine variant for nontoxic and effective reversal of conventional heparin and low-molecular-weight heparin anticoagulation. J Surg Res. 1996;63(1):280-286. 181. Dietrich CP, Shinjo SK, Moraes FA, et al. Structural fea- tures and bleeding activity of commercial low molecular weight heparins: neutralization by ATP and protamine. Semin Thromb Hemost. 1999;25(suppl 3):43-50. 182. Kuziej J, Litinas E, Hoppensteadt DA, et al. In vivo neu- tralization of unfractionated heparin and low-molecular- weight heparin by a novel salicylamide derivative. Clin Appl Thromb Hemost. 2010;16(4):377-386. 183. Monreal M, Vi as L, Monreal L, Lavin S, Lafoz E, Angles AM. Heparin-related osteoporosis in rats. A comparative study between unfractioned heparin and a low-molecular-weight heparin. Haemostasis. 1990;20(4):204-207. 184. M tzsch T, Bergqvist D, Hedner U, Nilsson B, Ostergaard P. Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rats. Thromb Haemost. 1990;63(3):505-509. 185. Muir J, Hirsh J, Weitz J, Andrew M, Young E, Shaughnessy SG. A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood. 1997;89(9):3263-3242. 186. Kock HJ, Handschin AE. Osteoblast growth inhibition by unfractionated heparin and by low molecular weight hep- arins: an in-vitro investigation. Clin Appl Thromb Hemost. 2002;8(3):251-255. 187. Folwarczna J, Janiec W, Gawor M, Pytlik M, Kaczmarczyk- Sedlak I, Nowi ska B. Effects of enoxaparin on histomor- phometric parameters of bones in rats. Pol J Pharmacol. 2004;56(4):451-457. renal function in patients on enoxaparin. J Clin Pharmacol. 2003;43(6):586-590. 156. Sanderink GJ, Guimart CG, Ozoux M-L, Jariwala NU, Shukla UA, Boutouyrie BX. 